Aethlon Medical (NASDAQ:AEMD) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report released on Thursday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a report on Monday, March 10th.

Aethlon Medical Price Performance

Shares of NASDAQ AEMD opened at $0.40 on Thursday. The stock’s fifty day moving average price is $0.38 and its two-hundred day moving average price is $0.49. Aethlon Medical has a one year low of $0.24 and a one year high of $1.06. The firm has a market cap of $6.47 million, a price-to-earnings ratio of -0.25 and a beta of 1.93.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.09. On average, equities analysts anticipate that Aethlon Medical will post -0.73 earnings per share for the current fiscal year.

Institutional Trading of Aethlon Medical

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter worth $25,000. Allegiance Financial Group Advisory Services LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter worth $26,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter worth $31,000. Virtu Financial LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter worth $81,000. Finally, Boothbay Fund Management LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter worth $186,000. 1.99% of the stock is owned by institutional investors and hedge funds.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.